151 related articles for article (PubMed ID: 38741123)
21. Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia.
Guo Y; Li Y; Shan Q; He G; Lin J; Gong Y
Int J Biochem Cell Biol; 2015 Aug; 65():1-11. PubMed ID: 25979368
[TBL] [Abstract][Full Text] [Related]
22. PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.
Ultimo S; Simioni C; Martelli AM; Zauli G; Evangelisti C; Celeghini C; McCubrey JA; Marisi G; Ulivi P; Capitani S; Neri LM
Oncotarget; 2017 Apr; 8(14):23213-23227. PubMed ID: 28390196
[TBL] [Abstract][Full Text] [Related]
23. Grb10 is involved in BCR-ABL-positive leukemia in mice.
Illert AL; Albers C; Kreutmair S; Leischner H; Peschel C; Miething C; Duyster J
Leukemia; 2015 Apr; 29(4):858-68. PubMed ID: 25249015
[TBL] [Abstract][Full Text] [Related]
24. Bag1 directly routes immature BCR-ABL for proteasomal degradation.
Tsukahara F; Maru Y
Blood; 2010 Nov; 116(18):3582-92. PubMed ID: 20675402
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia.
Koldehoff M; Elmaagacli AH
Methods Mol Biol; 2009; 487():451-66. PubMed ID: 19301661
[TBL] [Abstract][Full Text] [Related]
26. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
[TBL] [Abstract][Full Text] [Related]
27. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
Okabe S; Tauchi T; Tanaka Y; Sakuta J; Ohyashiki K
Oncotarget; 2016 Aug; 7(33):53116-53126. PubMed ID: 27437766
[TBL] [Abstract][Full Text] [Related]
29. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
[TBL] [Abstract][Full Text] [Related]
30. RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
Withey JM; Harvey AJ; Crompton MR
Leuk Res; 2006 May; 30(5):553-60. PubMed ID: 16260034
[TBL] [Abstract][Full Text] [Related]
31. Targeting bcr-abl transcripts with siRNAs in an imatinib-resistant chronic myeloid leukemia patient: challenges and future directions.
Koldehoff M
Methods Mol Biol; 2015; 1218():277-92. PubMed ID: 25319658
[TBL] [Abstract][Full Text] [Related]
32. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
33. Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells.
Jiang G; Huang Z; Yuan Y; Tao K; Feng W
J Hematol Oncol; 2021 Sep; 14(1):139. PubMed ID: 34488814
[TBL] [Abstract][Full Text] [Related]
34. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
Zhu XS; Lin ZY; Du J; Cao GX; Liu G
Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
[TBL] [Abstract][Full Text] [Related]
35. PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.
Wu N; Kurosu T; Oshikawa G; Nagao T; Miura O
Int J Oncol; 2013 Feb; 42(2):419-28. PubMed ID: 23233201
[TBL] [Abstract][Full Text] [Related]
36. Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells.
Hoshiko T; Kubota Y; Akisawa T; Watanabe T; Tanigawara K; Yano J; Kimura S
Invest New Drugs; 2020 Aug; 38(4):1012-1019. PubMed ID: 31650445
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia.
Koldehoff M; Steckel NK; Beelen DW; Elmaagacli AH
Clin Exp Med; 2007 Jun; 7(2):47-55. PubMed ID: 17609876
[TBL] [Abstract][Full Text] [Related]
38. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
39. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
Wu Y; Chen C; Sun X; Shi X; Jin B; Ding K; Yeung SC; Pan J
Clin Cancer Res; 2012 Apr; 18(7):1966-78. PubMed ID: 22447844
[TBL] [Abstract][Full Text] [Related]
40. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]